The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
Open accessAbstract
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2–3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1–2% per year for the next 10 years. Testing should be done 2–3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4–6 months for 1 year and, if stable, every 6–12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationPrevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423 · cited 1×
“2% of 21,463 residents of Olmsted County, Minnesota, 50 years of age or older (2).”
BackgroundSelf-citationClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Self-citationRajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J., Bradwell, A. R., Clark, R. J., Larson, D. R., Plevak, M. F., Dispenzieri, A., & Katzmann, J. A. (2005) · Blood · doi:10.1182/blood-2005-03-1038 · Cited by 702
Self-citationPérez-Persona, E., Vidriales, M.-B., Mateo, G., García-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martín-Nuñez, G., Alonso, J. M., de las Heras, N., et al. (2007) · Blood · doi:10.1182/blood-2007-05-088443 · Cited by 579
Dispenzieri, A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D., Benson, J., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2008) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 433
Self-citationSolitary plasmacytoma of bone and asymptomatic multiple myeloma
Dimopoulos, M. A., Moulopoulos, L. A., Maniatis, A., & Alexanian, R. (2000) · Blood · doi:10.1182/blood.v96.6.2037 · Cited by 397
Self-citationCesana, C., Klersy, C., Barbarano, L., Nosari, A., Crugnola, M., Pungolino, E. M., Gargantini, L., Granata, S., Valentini, M., & Morra, E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1625 · Cited by 259
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationWechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Multiple myeloma epidemiology and survival: A unique malignancy
Kazandjian, D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.004 · Cited by 765
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709974 · Cited by 647
Self-citationKumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Self-citationRöllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
Leung, N., Bridoux, F., Hutchison, C. A., Nasr, S. H., Cockwell, P., Fermand, J.-P., Dispenzieri, A., Song, K. W., & Kyle, R. A. (2012) · Blood · doi:10.1182/blood-2012-07-445304 · Cited by 548
Self-citationKim, J. H., Kim, J. W., Kim, Y. N., Kim, H. I., Kim, J. Y., Kwon, G. Y., Kim, K., & Jang, H. R. (2015) · Case Reports in Nephrology and Dialysis · doi:10.1159/000439267 · Cited by 538
Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
Self-citationDiagnosis of monoclonal gammopathy of renal significance
Bridoux, F., on behalf of the International Kidney and Monoclonal Gammopathy Research Group, Leung, N., Hutchison, C. A., Touchard, G., Sethi, S., Fermand, J.-P., Picken, M. M., Herrera, G. A., Kastritis, E., et al. (2015) · Kidney International · doi:10.1038/ki.2014.408 · Cited by 426
Self-citationUsmani, S. Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 394
Self-citationTargeting the bone marrow microenvironment in multiple myeloma
Kawano, Y., Moschetta, M., Manier, S., Glavey, S., Görgün, G. T., Roccaro, A. M., Anderson, K. C., & Ghobrial, I. M. (2015) · Immunological Reviews · doi:10.1111/imr.12233 · Cited by 391
Self-citationZavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0053-3 · Cited by 374
Terpos, E., Morgan, G., Dimopoulos, M. A., Drake, M. T., Lentzsch, S., Raje, N., Sezer, O., García-Sanz, R., Shimizu, K., Turesson, I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7901 · Cited by 352
Self-citationMolecular pathogenesis of multiple myeloma and its premalignant precursor
Kuehl, W. M., & Bergsagel, P. L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61188 · Cited by 334
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Dingli, D., Fonder, A. L., Hayman, S. R., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0077-4 · Cited by 303
Self-citationBone Marrow Microenvironment in Multiple Myeloma Progression
Manier, S., Sacco, A., Leleu, X., Ghobrial, I. M., & Roccaro, A. M. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/157496 · Cited by 301
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Bianchi, G., & Munshi, N. C. (2015) · Blood · doi:10.1182/blood-2014-11-568881 · Cited by 288
Quantitative MRI and spectroscopy of bone marrow
Karampinos, D. C., Ruschke, S., Dieckmeyer, M., Diefenbach, M., Franz, D., Gersing, A. S., Krug, R., & Baum, T. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25769 · Cited by 285
Rajkumar, S. V., Landgren, O., & Mateos, M.-V. (2015) · Blood · doi:10.1182/blood-2014-09-568899 · Cited by 269
Self-citationAffer, M., Chesi, M., Chen, W. D., Keats, J. J., Demchenko, Y. N., Tamizhmani, K., Garbitt, V. M., Riggs, D. L., Brents, L. A., Roschke, A. V., et al. (2014) · Leukemia · doi:10.1038/leu.2014.70 · Cited by 268
Self-citationSingle cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Ledergor, G., Weiner, A., Zada, M., Wang, S.-Y., Cohen, Y. C., Gatt, M. E., Snir, N., Magen, H., Koren-Michowitz, M., Herzog-Tzarfati, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0269-2 · Cited by 263
Self-citationFrontline therapy of multiple myeloma
Moreau, P., Attal, M., & Facon, T. (2015) · Blood · doi:10.1182/blood-2014-09-568915 · Cited by 244
Rajkumar, S. V., Gupta, V, Fonseca, R., Dispenzieri, A., Gonsalves, W. I., Larson, D., Ketterling, R. P., Lust, J. A., Kyle, R. A., & Kumar, S. K. (2013) · Leukemia · doi:10.1038/leu.2013.86 · Cited by 239
Self-citationNeben, K., Jauch, A., Hielscher, T., Hillengass, J., Lehners, N., Seckinger, A., Granzow, M., Raab, M. S., Ho, A. D., Goldschmidt, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4923 · Cited by 233
Genomic patterns of progression in smoldering multiple myeloma
Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., Martincorena, I., Dawson, K. J., Samur, M. K., Zamora, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05058-y · Cited by 222
Self-citationDhodapkar, M. V., Sexton, R., Waheed, S., Usmani, S., Papanikolaou, X., Nair, B., Petty, N., Shaughnessy, J. D., Hoering, A., Crowley, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515239 · Cited by 192
Self-citationLandgren, O., Hofmann, J. N., McShane, C. M., Santo, L., Hultcrantz, M., Korde, N., Mailankody, S., Kazandjian, D., Murata, K., Thoren, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1568 · Cited by 103
Self-citationPrevalence of smoldering multiple myeloma based on nationwide screening
Thorsteinsdóttir, S., Gíslason, G. K., Aspelund, T., Rögnvaldsson, S., Óskarsson, J. Þ., Sigurðardóttir, G. Á., Þórðardóttir, Á. R., Viðarsson, B., Önundarson, P. T., Agnarsson, B. A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02183-6 · Cited by 93
Self-citationCowan, A., Ferrari, F., Freeman, S. S., Redd, R., El-Khoury, H., Perry, J., Patel, V., Kaur, P., Barr, H., Lee, D. J., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00386-6 · Cited by 86
Self-citationLow serum mi R‐19a expression as a novel poor prognostic indicator in multiple myeloma
Hao, M., Zang, M., Wendlandt, E., Xu, Y., An, G., Gong, D., Li, F., Qi, F., Zhang, Y., Yang, Y., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29199 · Cited by 72
Mateos, M.-V., Martínez-López, J., Rodriguez Otero, P., González-Calle, V., Gonzalez, M. S., Oriol, A., Gutiérrez, N. C., Ríos-Tamayo, R., Rosiñol, L., Alvarez Rivas, M. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02771 · Cited by 39
Self-citationMonoclonal gammopathy of undetermined significance
Rajkumar, S. V., & Kumar, S. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412716 · Cited by 31
Self-citation(2023) · doi:10.1182/bloodadvances.2023011608 · Cited by 17
Jurczyszyn, A., & Suska, A. (2019) · Reference Module in Biomedical Sciences · doi:10.1016/b978-0-12-801238-3.11412-6 · Cited by 13
Hannich, M. J., Konen, F. F., Gag, K., Alkhayer, A., Türker, S. N., Budde, K., Nauck, M., Wurster, U., Dressel, A., Skripuletz, T., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1468 · Cited by 7
Metadata
- Authors
- Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., San Miguel, J., Avet-Loiseau, H., Hajek, R., Chen, W. M., Anderson, K. C., Ludwig, H., Sonneveld, P., Pavlovsky, S., Palumbo, A., Richardson, P. G., Barlogie, B., Greipp, P., Vescio, R., Turesson, I., Westin, J., Boccadoro, M., & on behalf of the International Myeloma Working Group
- Venue
- Leukemia
- Published
- 2010-04-22
- Volume
- 24
- Issue
- 6
- Pages
- 1121-1127
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2170515647
- Cited by
- 888
- References
- 23
- FWCI
- 29.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.